These findings suggest that anti-PD-1 antibodies combined with an Aim2-suppressed DC vaccine or Aim2 siRNA could be a new treatment strategy for patients with cold melanoma (Figure 3) [39]. This evidence concerns the gene PDCD1 and melanoma.